Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944682 | 1.00 | DPP4 (0.33) | DPP4FAPDPP7PREPDPP8 | |
| SCHEMBL5856414 | 0.98 | DPP7 (0.33) | DPP4FAPDPP7PREPDPP8 | |
| SCHEMBL691381 | 0.83 | SLC7A5 (0.38) | DPP4FAPDPP7PREPDPP8 | |
| SCHEMBL5074820 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL27173938 | 0.82 | CHRM5 (0.36) | — | |
| SCHEMBL28066960 | 0.82 | ALDH1A1 (0.41) | — | |
| SCHEMBL11887150 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL5874768 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL15153153 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL7718861 | 0.78 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945500-B | Mixing agonist based on GIP is for treating metabolic disorder and obesity | 印第安纳大学研究及科技有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109715185-A | Water soluble and chemically stable glucagon peptides | 印第安纳大学研究及科技有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108697756-A | HER2 peptide reagents and method | 密歇根大学董事会 | 2018-10-23 | — | — | CN | disclosed |
| CN-104583233-B | Show the analog of the glucagon of GIP receptor actives | 印第安纳大学研究及科技有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108383902-A | Insulin analog dimer | 印第安纳大学研究及科技有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104995207-B | β integrin-G protein α subunit binding interaction inhibitors | 伊利诺伊州大学理事会 | 2018-08-07 | — | — | CN | disclosed |
| CN-108271356-A | INCRETIN-INSULIN CONJUGATES | 印第安纳大学研究及科技有限公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-108064173-A | Partial insulin receptor agonists | 默沙东公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-104583232-B | Show the glucagon analogs of GIP receptor actives | 印第安纳大学研究及科技有限公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-104981251-B | Insulin analog dimers | 印第安纳大学研究及科技有限公司 | 2018-03-20 | — | — | CN | disclosed |
| CN-102834108-A | Glucagon antagonist-GIP agonist conjugates and compositions for treating metabolic disorders and obesity | UNIV INDIANA RES & TECH CORP | 2012-12-19 | — | — | CN | disclosed |
| CN-102448482-A | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | VAN ANDEL RES INST | 2012-05-09 | — | — | CN | disclosed |
| CN-102325539-A | Amide based glucagon superfamily peptide prodrugs | UNIV INDIANA RES & TECH CORP | 2012-01-18 | — | — | CN | disclosed |
| CN-102123723-A | Glucagon/GLP-1 receptor co-agonists | UNIV INDIANA RES & TECH CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102105159-A | GIP-based mixed agonists for the treatment of metabolic disorders and obesity | UNIV INDIANA RES & TECH CORP | 2011-06-22 | — | — | CN | disclosed |
| CN-102088989-A | Glucagon analogs with enhanced solubility and stability in physiological pH buffers | UNIV INDIANA RES & TECH CORP | 2011-06-08 | — | — | CN | disclosed |
| CN-101815723-A | immunomodulatory peptides | SYNTONIX PHARMACEUTICALS INC | 2010-08-25 | — | — | CN | disclosed |
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | DPP4 248/4885FAP 165/4885DPP7 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.